ATC Group: A02BC04 Rabeprazole

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A02BC04 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Drugs for acid related disorders
3
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4
Proton pump inhibitors
5
A02BC04
Rabeprazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
20 mg

Active ingredients in A02BC04

Active Ingredient
Description

Rabeprazole belongs to the class of anti-secretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonist properties, but suppress gastric acid secretion by the specific inhibition of the H+/K+ -ATPase enzyme (the acid or proton pump).

Medicines in this ATC group

Drug
Countries

Estonia Singapore

South Africa United States

South Africa

Singapore

Cyprus

Australia

Australia Austria Brazil Canada Cyprus ...

Hong Kong

South Africa

Estonia

Hong Kong

Hong Kong

Ecuador

Hong Kong

Hong Kong Ireland

Lithuania

Australia

Estonia

Estonia Lithuania Poland

Related product monographs

Title
Type
Country
Structured Product Labeling (SPL/PLR)
US
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
IE